

General Information	
Ministerial Decision Type	Miscellaneous
Report Title	Amendment to the Prescribed List 1 October 2022
Minister	Social Security
Signatory	Minister
Lead Department	Strategic Policy, Planning and Performance (SP3)
Lead Directorate	Public Policy (SP3)
Ministerial Decision Summary: Public or Absolutely/Qualified Exempt	Public
Date decision made if different to date 'Ministerial Decision Summary' signed.	02/09/2022
Report and Supplemental Report Details	
Report Author	Senior Policy Officer
Date of Report	02/09/2022
Supplementary Report Title <i>(If applicable)</i>	Insert Supplemental Report Title.
Supplementary Report Author <i>(If applicable)</i>	Insert Official Title Only.
Date of Supplementary Report <i>(If applicable)</i>	Select Date of Supplemental Report.
Ministerial Decision Report: Public or Absolutely/Qualified Exempt	Public
Relevant Case/Application/URN <i>(Only complete if making a decision related to an appeal where appropriate or allowed under legislation/case/application)</i>	Insert Relevant Case/Application.
Relevant Proposition Number <i>(Only complete if presenting Comments or if lodging an Amendment)</i>	Insert P. number.
Relevant Scrutiny Report <i>(Only complete if presenting a ministerial response)</i>	Insert S.R. number.
Associated Law(s) and/or Subordinate Legislation	Health Insurance (Jersey) Law 1967
Action required if recommendation agreed	Department to take necessary action.
Resource Implications	There are additional financial and/or manpower implications. Further detail is included in the detail section of the report.

Introduction

Further to Article 15, paragraphs (11) and (12), of the Health Insurance (Jersey) Law 1967, and having consulted with the Pharmaceutical Benefit Advisory Committee, the Minister decided to make amendments to the Prescribed List with effect from 1 October 2022.

The Pharmaceutical Benefit Advisory Committee (PBAC) met on 9 June 2022 to consider applications for changes to the Prescribed List and recommended the following changes

Recommendation

1. Items to be added to the Prescribed List from 1 October 2022

1.1. Ogluo (glucagon) 1 mg solution for injection in pre-filled pen for treatment of severe diabetic hypoglycaemia

1.2 Ranolazine 375mg, 500mg, 750mg modified-release tablets for treatment of stable angina

2. Items to be removed from the Prescribed List from 1 April 2023

2.1 The Committee recommended removal of the following products from the Prescribed List these being either discontinued or no longer routinely prescribed in primary care. Alternative products are available on the List where necessary.

Calmurid (Urea 10% / Lactic acid 5%) cream
Estradiol 40micrograms/24hours and 80micrograms/24hours transdermal patches (Elleste Solo™ MX)
Morphine sulfate 15mg/ 30mg suppositories
Phenobarbital 15mg/5mL elixir
Prazosin 1mg/ 2mg/ 5mg tablets
Ranitidine 150mg/ 300mg tablets
Ranitidine 75mg/5mL oral solution sugar free
Ranitidine 50mg/2ml solution for injection ampoules
Aluminium hydroxide 475mg capsules (Alu -Cap)
Aluminium hydroxide 500mg tablets
Amoxicillin 125mg/1.25mL oral suspension paediatric
Betamethasone 0.1% eye ointment
Bromocriptine 10mg capsules
Calcium carbonate 1.25g / colecalciferol 400unit tablets
Co -triamterzide 50/25mg tablets
Dihydrocodeine 10mg/5mL oral solution
Dipyridamole 200mg MR/ aspirin 25mg capsules
Dithranol 0.25% / 0.5% / 1% / 2% cream
Fluocinolone acetonide 0.025% / Neomycin 0.5% cream and ointment
Fluphenazine decanoate 100mg/mL / 25mg/mL / 50mg/0.5mL solution for injection ampoules
Glibenclamide 2.5mg/5mg tablets
Glyceryl trinitrate 300microgram sublingual tablets
Hydrocortisone 10% foam aerosol enema

Indometacin 75mg modified release capsules
Isopropyl alcohol 70% / Triclosan 0.5% topical solution
Isotretinoin 0.05% / erythromycin 2% gel
Levobunolol 0.5% eye drops
Levobunolol 0.5% eye drops 0.4ml unit dose preservative free
Methyl salicylate 50% ointment
Nedocromil 2% eye drops
Neostigmine 15mg tablet
Orphenadrine 50mg tablets
Pancrex gastro -resistant granules
Pancrex V gastro -resistant tablets
Pancrex V Forte gastroresistant tablets
Creon 40,000units GR capsules
Polymyxin B 10,000units/g / Bacitracin 500units/g ointment (Polyfax)
Sodium chloride 0.9% eye drops
Sotalol 200mg tablets
Tazarotene 0.05% / 0.1% gel (Zorac)
Testosterone 40mg capsules
Triclosan 1% / 2% liquid
Verapamil 120mg MR capsules

2.2 In addition, the Committee recommended removal of diamorphine injections (all strengths) from the Prescribed List as morphine injections are now recommended in Jersey palliative care guidelines

Detail

The Committee recommended addition of Ogluo (glucagon) injections to the Prescribed List for supply to patients with diabetes at risk of severe hypoglycaemia. It offers advantages over the currently available glucagon product including ready-to-use formulation with no need to reconstitute in an urgent situation, doesn't need to be stored in a fridge, and available in a lower strength suitable for children. While more expensive than the existing product, low levels of use (approx. 70 syringes per year) will limit overall cost impact.

The Committee recommended addition of Ranolazine 375mg, 500mg, 750mg modified-release tablets to the Prescribed List. It is used as an adjunct for the symptomatic treatment of stable angina pectoris in patients who are inadequately controlled or intolerant of first-line antianginal therapies. Ranolazine is recommended as a treatment option in national and international guidelines.

Financial impact

The overall financial impact of the above changes is expected to be an increase in net annual expenditure of up to £35,000.

The products recommended for removal from the List are either discontinued or not routinely used so their removal is not expected to have a financial impact.